ScholarLens Back to search
2021•Annals of OncologyOpen access

583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide

Vincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, Nicole Brighi, Giuseppe Schepisi, Alessandro Romanel, Chiara Casadei, Cristian Lolli, Giorgia Gurioli, I. Toma, Giulia Poti, Alberto Farolfi, Francesca Demichelis, G. Attard, Ugo De Giorgi

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Enzalutamide, Abiraterone, Prostate cancer, Medicine, Oncology, Androgen receptor, Internal medicine, Abiraterone acetate

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide — Research Paper | ScholarLens